Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

ClinicalTrials.gov ID: NCT02052648

Public ClinicalTrials.gov record NCT02052648. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly diagnosed glioblastoma patients with radiation and temozolomide, or in combination with vaccine therapies.

Study identification

NCT ID
NCT02052648
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
NewLink Genetics Corporation
Industry
Enrollment
160 participants

Conditions and interventions

Eligibility (public fields only)

Age range
16 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2014 (Type not available)
Primary completion
Apr 18, 2018 (Actual)
Completion
Jun 20, 2019 (Actual)
Last update posted
Mar 27, 2024

2014 – 2019

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Eden Medical Center Castro Valley California 94546 —
Cedars-Sinai Medical Center Los Angeles California 90048 —
UC Irvine Chao Family Comprehensive Cancer Center Orange California 92868 —
Moffitt Cancer Center Tampa Florida 33612 —
University Cancer and Blood Center Athens Georgia 30607 —
Children's Healthcare of Atlanta Atlanta Georgia 30342 —
Augusta University Augusta Georgia 30912 —
University of Chicago Chicago Illinois 60637 —
University of Iowa Hospitals and Clinics Iowa City Iowa 52242 —
University of Kentucy Lexington Kentucky 40536 —
John Nasseff Neuroscience Institute Minneapolis Minnesota 55407 —
University of New Mexico Comprehensive Cancer Center Albuquerque New Mexico 87131 —
Wake Forest Baptist Health Comprehensive Cancer Center Winston-Salem North Carolina 27157 —
Penn State Hershey Medical Center Hershey Pennsylvania 17033 —
Texas Oncology Austin Texas 78705 —
Huntsman Cancer Center Salt Lake City Utah 84112 —
Virginia Cancer Specialists Fairfax Virginia 22031 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02052648, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 27, 2024 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02052648 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →